(4-hydroxymethyl-3-methoxy-phenyl)-acetonitrile | 669002-84-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-hydroxymethyl-3-methoxy-phenyl)-acetonitrile
• 英文别名: [4-(Hydroxymethyl)-3-methoxyphenyl]acetonitrile；2-[4-(hydroxymethyl)-3-methoxyphenyl]acetonitrile
• CAS: 669002-84-0
• 化学式: C₁₀H₁₁NO₂
• 分子量: 177.203
• InChiKey: GBRLVADCWLZKRS-UHFFFAOYSA-N

物化性质

• 沸点：
  346.5±32.0 °C(Predicted)
• 密度：
  1.154±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20040242572A1

  公开（公告）日：2004-12-02

  The present invention relates to carboxamide compounds of general formula I 1 wherein the groups and residues A, B, W, X, Y, Z, R 1 , R 2 , R 3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及具有通式I的羧酰胺化合物 1 其中，A、B、W、X、Y、Z、R 1 、R 2 、R 3 和k的含义如权利要求1中所述。此外，本发明还涉及制备上述羧酰胺的方法以及含有至少一种根据本发明的羧酰胺的药物组合物。由于它们对MCH受体的拮抗活性，根据本发明的药物组合物适合用于治疗代谢紊乱和/或饮食紊乱，特别是肥胖症、厌食症、暴食症、糖尿病。
• PHENANTHROINDOLIZIDINE DERIVATIVE AND NFKB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：Ikeda Takashi

  公开号：US20110201637A1

  公开（公告）日：2011-08-18

  A novel compound having an excellent NFκB inhibitory effect is provided. Specifically disclosed is a compound represented by the following formula (1) or a salt thereof: wherein, R 1 represents a hydrogen atom, a lower alkyl group, or the like; R 2 represents a hydrogen atom, a lower alkyl group, a halogen atom, or the like; R 3 represents a hydrogen atom, a lower alkyl group, a hydroxyl group, or a halogen atom; R 4 represents a hydrogen atom or a lower alkyloxy group; R 5 represents a hydrogen atom, a lower alkyloxy group, a halogen atom, a hydroxyl group, or a methylenedioxy group formed together with R 6 or an isopropylidenedioxy group formed together with R 6 ; R 6 represents a hydrogen atom, a lower alkyloxy group, or a methylenedioxy group formed together with R 5 or an isopropylidenedioxy group formed together with R 5 ; R 7 represents a hydrogen atom or a lower alkyl group; and R 8 represents a hydrogen atom, a hydroxyl group, an amino group, a lower alkylcarbonyloxy group, or a halogen atom.

  提供一种具有优异的NFκB抑制效果的新化合物。具体披露的是以下式（1）或其盐的化合物：其中，R1代表氢原子，低碳基或类似物; R2代表氢原子，低碳基，卤素原子或类似物; R3代表氢原子，低碳基，羟基或卤素原子; R4代表氢原子或低碳基氧基; R5代表氢原子，低碳基氧基，卤素原子，羟基或与R6形成的亚甲二氧基或与R6形成的异丙亚甲基二氧基; R6代表氢原子，低碳基氧基或与R5形成的亚甲二氧基或与R5形成的异丙亚甲基二氧基; R7代表氢原子或低碳基; R8代表氢原子，羟基，氨基，低碳基羰基氧基或卤素原子。
• PHENANTHROINDOLIZIDINE DERIVATIVE AND NF B INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：Kabushiki Kaisha Yakult Honsha

  公开号：EP2351753A1

  公开（公告）日：2011-08-03

  A novel compound having an excellent NFκB inhibitory effect is provided. Specifically disclosed is a compound represented by the following formula (1) or a salt thereof: wherein, R1 represents a hydrogen atom, a lower alkyl group, or the like; R2 represents a hydrogen atom, a lower alkyl group, a halogen atom, or the like; R3 represents a hydrogen atom, a lower alkyl group, a hydroxyl group, or a halogen atom; R4 represents a hydrogen atom or a lower alkyloxy group; R5 represents a hydrogen atom, a lower alkyloxy group, a halogen atom, a hydroxyl group, or a methylenedioxy group formed together with R6 or an isopropylidenedioxy group formed together with R6; R6 represents a hydrogen atom, a lower alkyloxy group, or a methylenedioxy group formed together with R5 or an isopropylidenedioxy group formed together with R5; R7 represents a hydrogen atom or a lower alkyl group; and R8 represents a hydrogen atom, a hydroxyl group, an amino group, a lower alkylcarbonyloxy group, or a halogen atom.

  本研究提供了一种具有优异 NFκB 抑制作用的新型化合物。具体公开了由下式（1）代表的化合物或其盐： 其中，R1 代表氢原子、低级烷基或类似物； R2 代表氢原子、低级烷基、卤素原子或类似物； R3 代表氢原子、低级烷基、羟基或卤素原子； R4 代表氢原子或低级烷氧基； R5 代表氢原子、低级烷氧基、卤素原子、羟基或与 R6 共同形成的亚甲基二氧基或与 R6 共同形成的亚异丙基二氧基； R6 代表氢原子、低级烷氧基或与 R5 共同形成的亚甲基二氧基或与 R5 共同形成的亚异丙基二氧基； R7 代表氢原子或低级烷基；以及 R8 代表氢原子、羟基、氨基、低级烷基羰氧基或卤原子。
• NEUE CARBONS UREAMID-VERBINDUNGEN MIT MCH-ANTAGONISTISCHER W IRKUNG, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL UND VERFAHREN ZU IHRER HERSTELLUNG
  申请人：BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

  公开号：EP1534689A1

  公开（公告）日：2005-06-01
• US8569327B2
  申请人：——

  公开号：US8569327B2

  公开（公告）日：2013-10-29